Group 4 Medulloblastoma is a rare disease that mostly affects pediatric patients, in which aberrant SRC signaling was identified as a hallmark of the disease
_256_384.jpg)
The deal will be financed by Rs 300 crore of internal accruals and Rs 350 crore of borrowings
Terran to advance the development of two of Sanofi's Phase 3 CNS therapeutics
Ind-Ra expects FY22 IPM to have witnessed 15% YoY sales growth, higher than the 8%-10% observed over the past five years, aided by the base effect
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
Agreement builds on 15 years of successful collaboration between AbbVie and Richter, including globally launched cariprazine products
Experts will speak about primary tumours of the nervous system and also the tumours of other body parts which get metastasized to the nervous system
Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders
Alongside brand refresh, the leading clinical trial technology company announces eConsent and eCOA offerings to better support the patient clinical trial journey
Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa
Subscribe To Our Newsletter & Stay Updated
